A
APREA THERAPEUTICS INC
NASDAQ: APRE (Aprea Therapeutics, Inc.)
Kemas kini terakhir: 13 jam lalu0.715
-0.06 (-8.31%)
| Penutupan Terdahulu | 0.780 |
| Buka | 0.783 |
| Jumlah Dagangan | 76,252 |
| Purata Dagangan (3B) | 377,908 |
| Modal Pasaran | 8,853,685 |
| Harga / Buku (P/B) | 0.230 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -2,514.78% |
| EPS Cair (TTM) | -2.34 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -57.30% |
| Nisbah Semasa (MRQ) | 5.90 |
| Aliran Tunai Operasi (OCF TTM) | -13.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.46 M |
| Pulangan Atas Aset (ROA TTM) | -35.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -59.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Aprea Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
0.3
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.30 |
|
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.90% |
| % Dimiliki oleh Institusi | 40.94% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Aigh Capital Management Llc | 31 Mar 2026 | 1,015,541 |
| Vestal Point Capital, Lp | 31 Mar 2026 | 350,000 |
| Sphera Funds Management Ltd. | 31 Mar 2026 | 270,000 |
| Hightower Advisors, Llc | 31 Mar 2026 | 13,864 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BIZZARI JEAN-PIERRE | 0.729 | - | 3,135 | 2,285 |
| DUEY MARC | 0.729 | - | 3,135 | 2,285 |
| GRISSINGER MICHAEL | 0.729 | - | 3,135 | 2,285 |
| GRUIA GABRIELA | 0.729 | - | 3,135 | 2,285 |
| HENNEMAN JOHN B III | 0.729 | - | 3,135 | 2,285 |
| PAMUKCU RIFAT | 0.729 | - | 3,135 | 2,285 |
| PETERS RICHARD | 0.729 | - | 3,135 | 2,285 |
| SEIZINGER BERND R. | 0.729 | - | 3,135 | 2,285 |
| Jumlah Keseluruhan Kuantiti Bersih | 25,080 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 18,283 | |||
| Purata Pembelian Keseluruhan ($) | 0.729 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SEIZINGER BERND R. | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,135 | 0.729 | 2,285 |
| PAMUKCU RIFAT | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,135 | 0.729 | 2,285 |
| DUEY MARC | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,135 | 0.729 | 2,285 |
| BIZZARI JEAN-PIERRE | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,135 | 0.729 | 2,285 |
| HENNEMAN JOHN B III | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,135 | 0.729 | 2,285 |
| PETERS RICHARD | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,135 | 0.729 | 2,285 |
| GRUIA GABRIELA | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,135 | 0.729 | 2,285 |
| GRISSINGER MICHAEL | Pengarah | 16 Jun 2026 | Diperolehi (+) | 3,135 | 0.729 | 2,285 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |